The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 13 May 2002 doi:10.1084/jem.20012100
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 442K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schuler-Thurner, B.
Right arrow Articles by Schuler, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schuler-Thurner, B.
Right arrow Articles by Schuler, G.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Melanoma
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© Rockefeller University Press, 0022-1007/2002/5/1279/ $5.00
The Journal of Experimental Medicine, Volume 195, Number 10, May 20, 2002 1279-1288

Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells

Beatrice Schuler-Thurner1, Erwin S. Schultz1, Thomas G. Berger1, Georg Weinlich2, Susanne Ebner2, Petra Woerl1, Armin Bender1, Bernadette Feuerstein1, Peter O. Fritsch2, Nikolaus Romani2 and Gerold Schuler1

1 Department of Dermatology, University Hospital of Erlangen, D-91052 Erlangen, Germany
2 Department of Dermatology, University of Innsbruck, A-6020 Innsbruck, Austria

Address correspondence to Gerold Schuler, Dept. of Dermatology, University Hospital of Erlangen, Hartmannstr. 14, D-91052 Erlangen, Germany. Phone: 49-9131-85-1006; Fax: 49-9131-85-6175; E-mail: schuler{at}derma.imed.uni-erlangen.de

There is consensus that an optimized cancer vaccine will have to induce not only CD8+ cytotoxic but also CD4+ T helper (Th) cells, particularly interferon (IFN)-{gamma}–producing, type 1 Th cells. The induction of strong, ex vivo detectable type 1 Th cell responses has not been reported to date. We demonstrate now that the subcutaneous injection of cryopreserved, mature, antigen-loaded, monocyte-derived dendritic cells (DCs) rapidly induces unequivocal Th1 responses (ex vivo detectable IFN-{gamma}–producing effectors as well as proliferating precursors) both to the control antigen KLH and to major histocompatibility complex (MHC) class II–restricted tumor peptides (melanoma-antigen [Mage]-3.DP4 and Mage-3.DR13) in the majority of 16 evaluable patients with metastatic melanoma. These Th1 cells recognized not only peptides, but also DCs loaded with Mage-3 protein, and in case of Mage-3DP4–specific Th1 cells IFN-{gamma} was released even after direct recognition of viable, Mage-3–expressing HLA-DP4+ melanoma cells. The capacity of DCs to rapidly induce Th1 cells should be valuable to evaluate whether Th1 cells are instrumental in targeting human cancer and chronic infections.

Key Words: dendritic cells • vaccination • CD4+ T cells • T helper cells • tumor immunity


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS